AQST director granted 50,500 stock options
Aquestive Therapeutics director John Cochran received a grant of 50,500 stock options on Common Stock as compensation.
Rhea-AI Filing Summary
Aquestive Therapeutics director John Cochran received a grant of 50,500 stock options on Common Stock as compensation. These options have an exercise price of $3.99 per share and expire on June 10, 2036. All 50,500 underlying shares vest on June 10, 2027, if he continues serving the company through that date.
Following this filing, Cochran directly holds 99,486 shares of Common Stock, separate from the new option award. The grant increases his potential future equity exposure but involves no open-market buying or selling of shares at this time.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 50,500 shares
Grant/Award
2 txns
Insider
Cochran John
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Purchase) | 50,500 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Purchase) — 50,500 contracts (Direct);
Common Stock — 99,486 shares (Direct)
Footnotes (1)
- F1. The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Mr. Cochran's continuous service with the Issuer from the grant date through the applicable vesting date.
Key Figures
Options granted: 50,500 options
Exercise price: $3.99 per share
Option expiration: June 10, 2036
+2 more
5 metrics
Options granted
50,500 options
Stock Option (Right to Purchase) grant on common stock
Exercise price
$3.99 per share
Conversion or exercise price for granted options
Option expiration
June 10, 2036
Expiration date of stock option award
Vesting date
June 10, 2027
100% of underlying shares vest on this date
Common shares held
99,486 shares
Direct common stock ownership after reported transactions
Key Terms
Stock Option (Right to Purchase), exercise price, vesting, continuous service
4 terms
Stock Option (Right to Purchase) financial
"Security title listed as "Stock Option (Right to Purchase)" for the grant"
exercise price financial
"Conversion or exercise price set at 3.9900 per share for the options"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
continuous service financial
"Subject to Mr. Cochran's continuous service with the Issuer from the grant date"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did John Cochran report in this Form 4 for Aquestive Therapeutics (AQST)?
John Cochran reported receiving a grant of 50,500 stock options on Aquestive Therapeutics common shares. The filing also shows he directly holds 99,486 common shares after the reported transactions, providing transparency on his current equity-based compensation and ownership.
What are the key terms of John Cochran’s 50,500 AQST stock options?
Cochran’s 50,500 stock options carry a $3.99 exercise price per share and expire on June 10, 2036. They relate to 50,500 underlying shares of common stock and were granted as an award, not acquired in the open market.
When do John Cochran’s newly granted AQST options vest?
All 50,500 options vest on June 10, 2027, in a single tranche. Vesting is contingent on Cochran’s continuous service with Aquestive Therapeutics from the grant date through that vesting date, aligning the award with ongoing board service.
What underlying security is tied to John Cochran’s AQST stock options?
The stock options relate to Aquestive Therapeutics common stock as the underlying security. Each option is exercisable into one share of common stock, with 50,500 underlying shares associated with the grant, subject to vesting and future exercise decisions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
